Litcius/Paper detail

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Pietro Lampertico, Marı́a Buti, Scott Fung, Sang Hoon Ahn, Wan‐Long Chuang, Won Young Tak, Alnoor Ramji, Chi-Yi Chen, Edward Tam, Ho Bae, Xiaoli Ma, John F. Flaherty, Anuj Gaggar, Audrey Lau, Yang Liu, George Y. Wu, Vithika Suri, Susanna K. Tan, G. Mani Subramanian, Huy N. Trinh, Seung Kew Yoon, Kosh Agarwal, Young‐Suk Lim, Henry Lik‐Yuen Chan

2020˜The œLancet. Gastroenterology & hepatology139 citationsDOI

Topics & Concepts

Tenofovir alafenamideTenofovirMedicineChronic hepatitisDouble blindVirologyPharmacologyInternal medicineHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyVirusPlaceboPathologyAlternative medicineHepatitis B Virus StudiesHIV/AIDS drug development and treatmentHepatitis C virus research
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study | Litcius